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Abstract
Background: Previous studies reported high C-reactive protein (CRP) levels in Indigenous Australians, which may
contribute to their high risk of cardiovascular disease. We compared CRP levels in Indigenous Australians and the
general population, accounting for obesity and other risk factors.
Methods: Cross-sectional study of CRP and risk factors (weight, height, waist and hip circumferences, blood
pressure, lipids, blood glucose, and smoking status) in population-based samples from the Diabetes and Related
conditions in Urban Indigenous people in the Darwin region (DRUID) study, and the Australian Diabetes, Obesity
and Lifestyle study (AusDiab) follow-up.
Results: CRP concentrations were higher in women than men and in DRUID than AusDiab. After multivariate
adjustment, including waist circumference, the odds of high CRP (>3.0 mg/L) in DRUID relative to AusDiab were
no longer statistically significant, but elevated CRP was still more likely in women than men. After adjusting for BMI
(instead of waist circumference) the odds for elevated CRP in DRUID participants were still higher relative to
AusDiab participants among women, but not men. Lower HDL cholesterol, impaired glucose tolerance (IGT), and
higher diastolic blood pressure were associated with having a high CRP in both men and women, while current
smoking was associated with high CRP in men but not women.
Conclusions: High concentrations of CRP in Indigenous participants were largely explained by other risk factors, in
particular abdominal obesity. Irrespective of its independence as a risk factor, or its aetiological association with
coronary heart disease (CHD), the high CRP levels in urban Indigenous women are likely to reflect increased
vascular and metabolic risk. The significance of elevated CRP in Indigenous Australians should be investigated in
future longitudinal studies.
Background
C-reactive protein (CRP) is an acute phase protein
synthesised predominantly by the liver [1]. Epidemiolo-
gical evidence suggests that CRP is associated with cor-
onary heart disease (CHD) [2]; diabetes and the
metabolic syndrome [3]. High CRP has been reported in
Indigenous Australians, and may contribute to or be a
marker for their elevated risk of CHD [4]. In a remote
Indigenous population, over 50% of participants had a
CRP above 3.0 mg/L, representing high risk [4], com-
pared with only 25% in the Busselton Study (mainly
non-Indigenous) [5]. Approximately 60% of high CRP in
Busselton could be attributed to smoking, body mass
index (BMI), blood pressure, diabetes, total cholesterol,
triglycerides and low HDL cholesterol [5]. These tend to
be worse in Indigenous Australians and could contribute
to elevated CRP concentrations [6,7].* Correspondence: hodgea@unimelb.edu.au1University of Melbourne, Department of Medicine, St Vincent’s Hospital,
Melbourne, Australia
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Other studies have variously shown that women had
CRP concentrations higher than men [8-11] (including a
study of Indigenous Australians [4]), similar to men [5]
or lower than men [12]. Oral contraceptive and hor-
mone replacement therapy use are both associated with
higher CRP [5,8,9,13] and may contribute to higher
levels sometimes seen in women. Traditional risk fac-
tors, particularly obesity, are also associated with CRP
[4,5,8-13]. Socioeconomic factors have also been related
to levels of CRP [14] and other inflammatory markers
[15,16].
The aim of this study was to compare CRP in an
urban Indigenous population and the general Australian
population, and to determine the contribution of other
risk factors to any differences observed. In view of the
different associations between BMI and CRP in men
and women previously observed in Aboriginal Austra-
lians [4], men and women were analysed separately.
Methods
Study population
The Diabetes and Related conditions in Urban Indigen-
ous people in the Darwin region (DRUID) study was
established to provide information on the prevalence of
diabetes and diabetes-related complications among Indi-
genous Australians in an urban area [17]. Eligible parti-
cipants were aged 15 years or more who identified as
Aboriginal and/or Torres Strait Islander, had lived
within a defined geographic region in and around the
city of Darwin for at least 6 months, and did not live in
an institutional dwelling. A sampling frame was not
available, but using available data we estimate that 14%
of eligible persons participated. Comparison with
national census data and data from the Northern Terri-
tory Department of Health and Community Services
suggested that the participants were more likely to be
female and participating females tended to be older than
the target population [17]. A total of 1004 people had at
least one measurement performed during 2003-05 [17].
The Australian Diabetes, Obesity and Lifestyle study
(AusDiab) is a national, population-based, longitudinal
survey of diabetes and associated risk factors in Austra-
lians ≥25 years of age, which commenced in 1999. Of the
original cohort (n = 11,247, response rate 37%, 10,788
participants were eligible (ie not deceased, withdrawn
from study, moved overseas, moved to high-care nursing
facility or with chronic/terminal disease) for the 5-year
follow-up in 2004-2005, when CRP was measured. A
total of 6537 (60.6%) AusDiab participants returned for
follow-up assessment. Compared with those who did not
attend follow-up, attendees were likely to be better edu-
cated, healthier and not to smoke [18].
The current analysis was limited to people aged 30-64
years, as there were no AusDiab participants aged <30
and very few DRUID participants aged ≥65. Those with
incomplete data were excluded from analysis, as were
women who were pregnant (n = 13), using hormone
replacement therapy (n = 311) or the oral contraceptive
pill (n = 184) as these women might be expected to
have elevated CRP levels [5]. The remaining 512 DRUID
participants and 2823 AusDiab participants were
included.
Study design
AusDiab and DRUID followed similar protocols. Eligible
participants who gave consent underwent a health
examination including the collection of blood and urine
samples, clinical and anthropometric measurements, and
administration of questionnaires.
A 2-hour oral glucose tolerance test was administered
to all participants who gave consent, with the exception
of those taking tablets or insulin for previously diag-
nosed diabetes, and those who were pregnant. Partici-
pants were classified as having diabetes if they met any
of the following criteria: 1) fasting plasma glucose (FPG)
≥7.0 mmol/L; 2) 2-hour plasma glucose (2 hPG) ≥11.1
mmol/L; or 3) previously diagnosed as having diabetes
and currently taking tablets and/or insulin for diabetes.
Among participants who were not currently taking
tablets and/or insulin for diabetes, impaired glucose tol-
erance (IGT) was considered present if FPG <7.0 mmol/
L and 2 hPG ≥ 7.8 and <11.1 mmol/L; impaired fasting
glucose (IFG) was considered present if FPG was ≥ 6.1
and <7.0 mmol/L, and 2 hPG was less than 7.8 mmol/L
[19]. Fifty two participants who were not originally clas-
sified but had fasting glucose < 6.1 mmol/l were consid-
ered to have normal glucose tolerance.
Plasma high sensitivity (hs)-CRP measurement in
DRUID was performed at the Clinical Trials Laboratory
(Flinders Medical Centre, Bedford Park, SA) by immu-
noturbidimetry using a Hitachi 917 analyzer (Hitachi
Ltd., Tokyo, Japan) and Roche reagents. CRP in Aus-
Diab was measured by chemiluminescent enzyme
immunoassay (Immulite DPC 2000, CA). Details of data
collection including blood sampling, blood pressure
measurement, anthropometry and biochemical methods
are described in detail elsewhere [17,20].
Statistical analysis
Where CRP was treated as a continuous variable it was
logn transformed. A categorical variable was also created
dividing CRP according to the American Heart Associa-
tion (AHA) recommendations [21]: low risk (<1.0 mg/
L); average risk (≥1.0 to 3.0 mg/L); and high risk (≥3.0
mg/L), which was further divided into ≥3.0 & < 10.0
and ≥10.0 mg/L. The AHA recommends that CRP levels
above 10 mg/L are likely due to acute inflammation and
should be ignored [21]. However, in a remote
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Indigenous group, CRP levels across the range were
maintained over a median 829 days [22], and we have
not excluded these values.
Associations between geometric mean CRP levels and
likely confounders (age and obesity) were plotted for the
4 groups: AusDiab men, AusDiab women, DRUID men
and DRUID women. BMI was categorised as: under-
weight (BMI <18.5 kg/m2); normal weight (BMI 18.5-
24.9 kg/m2); overweight (BMI 25-29.9 kg/m2); and obese
(BMI 30+ kg/m2) [23], but because of the small number
of people in the underweight category, the first two
groups were collapsed. Waist circumference was cate-
gorised as: low risk for obesity associated metabolic
complications (<94 cm for men & < 80 cm for women);
increased risk (94-101.9 cm for men & 80-87.9 cm for
women); and substantially increased risk (> 102 cm for
men & > 88 cm for women) [23].
Several previous studies have reported different asso-
ciations between CRP and obesity or other risk factors
for men and women [4,9-11]; hence all analyses are per-
formed separately for men and women. Interaction
terms were calculated for measures of obesity (waist and
BMI) by gender and tested in multivariate models to
determine whether in fact gender modified the associa-
tions between obesity and CRP. Logistic regression with
CRP >3.0 (yes/no) as the dependent variable was used
to identify variables associated with elevated CRP. Vari-
ables included in these models were: population (Aus-
Diab, DRUID), age group (30-34, 35-44, 45-54, 55-64),
total cholesterol (mmol/L), logn triglycerides (mmol/l),
HDL cholesterol (mmol/L), systolic blood pressure
(mmHg), diastolic blood pressure (mmHg), glucose tol-
erance status (normal, IFG, IGT, diabetes), smoking sta-
tus (smoker, non-smoker) and either BMI (kg/m2) or
waist circumference (cm) as continuous variables. Tri-
glyceride values were natural log transformed to
improve normality. Variables other than triglycerides
were normally distributed. Models were also computed
stratifying on population, to evaluate the association of
gender with elevated CRP. Models were repeated with
CRP > 10 mg/L (yes/no) as the outcome.
Ethical approval
Ethics approval for DRUID was given by the combined
Human Research Ethics Committee of Northern Terri-
tory Department of Health and Community Services
and Menzies School of Health Research, Darwin. The
ethics committee of the International Diabetes Institute
approved the AusDiab study. Informed consent was
obtained from all participants.
Results
DRUID participants were on average 6-8 years younger
than AusDiab participants (Table 1). Mean BMIs were
all in the overweight range; DRUID women had a mean
around 2 units higher than AusDiab women. The differ-
ences in waist to hip ratio (WHR) and waist circumfer-
ence between the two groups of women were marked.
DRUID participants were more likely to have diabetes
and more likely to smoke than AusDiab participants.
DRUID men and women had mean CRP values in the
high-risk range ≥ 3.0 mg/L, and DRUID women had a
mean around twice that of AusDiab women.
Figure 1 shows mean CRP levels according to cate-
gories of BMI (a) and waist circumference (b) for each
study group. Among those in the smallest category of
waist circumference, DRUID women show little evi-
dence of elevated CRP. With increasing obesity, mean
CRP levels increased more steeply for DRUID women
than for other groups. Excluding the 8 men and 29
women with BMI less than 18.5 kg/m2 did not appreci-
ably change the results.
Figure 2 shows mean CRP levels according to age for
each group. In general, CRP increased slightly with age
up to 65 years, most notably in DRUID women; but for
DRUID men CRP was highest among those aged 35-44
years.
In unadjusted models, the OR for elevated CRP in
DRUID men relative to AusDiab men was 2.58 (95%CI
1.84-3.57); for women the OR was 2.89 (2.26-3.70).
Interactions between measures of obesity (BMI and
waist) and gender were significant (p = 0.003 for both
BMI and waist circumference) in multivariate models.
Table 2 shows odds ratios (ORs) for multivariate logistic
regression with elevated CRP (≥3.0 mg/L, yes/no) as the
dependent variable, and waist circumference as the mea-
sure of obesity. After adjustment, the OR for elevated
CRP in DRUID relative to AusDiab was no longer sig-
nificantly different to unity. For both men and women,
waist circumference, HDL cholesterol (inverse), diastolic
blood pressure, and glucose tolerance were associated
with elevated CRP. Smoking in men, but not women
was also associated with elevated CRP. Using forward
stepwise logistic regression revealed that obesity,
whether measured as waist circumference or BMI, was
the first variable to be entered in models for men and
women and for DRUID and AusDiab participants.
Stratifying by population indicated that for both
DRUID and AusDiab participants, women were more
likely to have an elevated CRP than men, after multi-
variate adjustment: OR for women relative to men in
AusDiab 4.31 (95%CI 3.47-5.35), and DRUID 2.95 (95%
CI 1.82-4.78). If BMI were used as the measure of obe-
sity in the multivariate model, population remained as a
significant determinant of CRP in women (OR for
DRUID relative to AusDiab 1.47, 95%CI 1.01-2.13), but
not for men (OR 1.28, 95%CI 0.85-1.94). Models were
also computed including HOMA insulin resistance, but
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although this was associated significantly with CRP, its
inclusion did not change the results appreciably.
Models including the same covariates were also fitted
with the dependent variable as CRP ≥ 10.0 mg/L (yes/
no). The OR for extreme CRP for DRUID males relative
to AusDiab males was 1.55 (95%CI 0.83-2.89), and for
DRUID females relative to AusDiab females 1.74 (95%CI
1.12-2.71). Stratifying by population, the OR for extreme
CRP in women relative to men was 4.57 (95%CI 3.19-
6.56) in AusDiab, and 3.62 (95%CI 2.07-6.35) in DRUID.
Discussion
CRP concentrations in urban Indigenous participants
from DRUID were higher than in the general population
sample; Indigenous women had particularly elevated
CRP levels. In men and women from both studies, CRP
was strongly associated with waist circumference and
BMI. Among those in the smallest waist circumference
category, CRP levels were not elevated in DRUID
women. After adjusting for waist circumference and
other potential confounders, the risk of elevated CRP in
DRUID was not significantly different to that for
AusDiab, although women still had more elevated CRP
than men. In men and women, having lower HDL cho-
lesterol, impaired glucose tolerance (IGT), and higher
diastolic blood pressure were also associated with having
a high CRP, while current smoking was associated with
high CRP in men but not women. The results for a CRP
of 10.0 mg/l or above suggested that such extreme
values were more common in DRUID women than Aus-
Diab women, and in women than men, even after
accounting for other risk factors.
The high CRP concentrations in this urban Indigenous
population are consistent with data for an isolated
Aboriginal community, where over 50% of participants
had an elevated CRP [4]. Data from a remote Indigen-
ous Island community were also compared with pub-
lished data from different countries, demonstrating the
relatively high CRP concentrations in the Indigenous
group, in which 39% of men and 18% of women had
CRP > 10 mg/L [24].
Wang and Hoy [24] showed that from around age 10,
CRP levels rose with age and were always higher in
females than males. Our unadjusted data also suggest
Table 1 Characteristics of study populations.
DRUID AUSDIAB
Variable Men n = 167 Women* n = 345 Men n = 1391 Women* n = 1432
Mean ± SD
Age (yrs) 43.2 ± 8.7 44.5 ± 8.9 50.9 ± 8.5 50.3 ± 8.4
BMI (kg/m2) 28.8 ± 5.6 29.7 ± 7.7 28.0 ± 4.5 27.7 ± 6.0
WHR 0.98 ± 0.07 0.90 ± 0.10 0.94 ± 0.07 0.82 ± 0.06
Waist (cm) 99.9 ± 14.1 97.5 ± 17.1 98.2 ± 12.0 87.2 ± 13.8
Systolic blood pressure (mmHg) 124.5 ± 16.4 117.8 ± 16.8 124.1 ± 17.7 115.4 ± 17.7
Diastolic blood pressure (mmHg) 79.5 ± 10.3 75.5 ± 9.3 73.3 ± 9.1 66.0 ± 9.7
Total cholesterol (mmol/L) 5.40 ± 1.33 5.17 ± 0.94 5.19 ± 0.94 5.25 ± 0.97
HDL (mmol/L) 1.02 ± 0.32 1.17 ± 0.33 1.25 ± 0.31 1.56 ± 0.39
Geometric mean(95%CI)
Fasting glucose (mmol/L) 6.04(5.77-6.32) 5.85(5.67-6.04) 5.48(5.44-5.52) 5.23(5.19-5.27)
CRP (mg/L) 3.43(2.68-3.63) 4.65(4.10-5.27) 1.94(1.84-2.04) 2.16(2.03-2.29)
Triglycerides (mmol/L) 2.13(1.93-2.35) 1.58(1.49-1.67) 1.43(1.39-1.47) 1.10(1.07-1.13)
Fibrinogen 3.69(3.51-3.89) 3.82(3.68-3.97) 2.70(2.67-2.74) 2.86(2.82-2.89)
Fasting Insulin (mU/L)** 9.11(8.16-10.18) 10.41(9.54-11.37) 7.56(7.31-7.83) 6.94(6.72-7.18)
HOMA-IR** 2.45(2.15-2.78) 2.71(2.45-3.00) 1.84(1.77-1.91) 1.61(1.55-1.67)
Percentages
Glucose tolerance
Diabetes 23.3 25.2 6.8 5.4
IFG/IGT 19.8 16.5 12.8 9.5
Normal 56.9 58.3 80.4 85.1
Smoking status
Current 45.5 42.9 13.0 8.9
Former 28.1 22.0 33.9 27.6
Never 21.0 27.2 49.4 59.6
*Women who are pregnant, using HRT or oral contraceptives are excluded.
**People with known diabetes on insulin (AusDiab), or insulin/tablets (DRUID) are excluded from these estimates.
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increasing CRP with age, but in the multivariate analysis
this was no longer seen. It is possible that the associa-
tion between CRP and age was due to the increase in
abdominal obesity with age, and so was lost once waist
circumference was accounted for.
Our results, and the results from Shemesh et al [4],
suggest that in the absence of obesity, women do not
have elevated CRP relative to men. Similar CRP levels
were also reported among lean Chinese men and
women (median CRP men 0.84; women 0.93 mg/L) [25].
In a population-based study in Japan, men had higher
CRP levels than women, but participants were relatively
lean and CRP concentrations were extremely low, with a
median for men of 0.16 mg/L and for women 0.09 mg/L
[12]. Men and women from the Dallas Heart Study in
the lowest tertile of fat mass (by DEXA) also did not
show differences in CRP concentrations [26].
Other studies have shown steeper increases in CRP in
association with risk factors in women relative to men.
In an Israeli study [10]and in the Framingham Offspring
Study [11], men with no metabolic syndrome compo-
nents had a slightly higher CRP than women, but as the
number of components increased, CRP rose more stee-
ply in women than men, and there were significant
interactions between number of components and sex
[10,11]. Similarly in the Dallas Heart Study, CRP rose
more steeply across BMI groups in women than in men,
so that at BMI > 30 kg/m2, CRP levels in women were
about twice those in men [9]. Among Aboriginal
Figure 1 Geometric mean CRP. a) Geometric mean CRP by BMI
category and study group. <25 kg/m2 white bars. 25-30 kg/m2 grey
bars. 30+ kg/m2 black bars. b) Geometric mean CRP by waist
circumference category and study group. <94 cm men; <80 cm
women white bars. 94-101.9 cm men; 80-87.9 cm women grey bars.
>102 cm men; 88 cm women black bars
Figure 2 Geometric mean CRP by age and study group. 30-34
years white bars. 35-44 years diagonal striped bars. 45-54 years grey
bars. 55-64 years black bars
Table 2 Odds ratios and 95% confidence intervals (OR,
95% CI) in multivariate models for factors associated
with the presence of elevated CRP (>3.0 mg/L) in DRUID
and AusDiab.
Men Women
Variable OR 95%CI OR 95%CI
Study
AusDiab 1.00 1.00
DRUID 1.30 0.86-1.98 1.04 0.72-1.50
Age
30-34 1.00 1.00
35-44 0.77 0.45-1.31 0.85 0.51-1.43
35-54 0.73 0.43-1.22 0.86 0.52-1.43
55-64 0.78 0.46-1.32 0.91 0.54-1.56
Waist circumference (cm) 1.06 1.05-1.07 1.07 1.06-1.09
Glucose tolerance
Normal 1.00 1.00
IFG 1.47 0.89-2.42 1.61 0.86-3.03
IGT 1.70 1.14-2.53 2.60 1.62-4.16
Diabetes 2.11 1.38-3.24 1.43 0.90-2.25
Smoking status
Current 1.00 1.00
Non-Smoker 0.47 0.34-0.64 1.00 0.71-1.41
HDL (mmol/L) 0.42 0.25-0.69 0.61 0.41-0.91
Total cholesterol (mmol/L) 1.08 0.94-1.23 1.07 0.93-1.22
Logn triglycerides (mmol/l) 0.94 0.71-1.26 1.28 0.93-1.78
Diastolic BP (mmHg) 1.02 1.00-1.04 1.02 1.00-1.04
Systolic BP (mmHg) 0.99 0.98-1.00 1.00 0.99-1.01
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Australians from an isolated rural community there was
a strong linear association between CRP and BMI in
women, but no association in men [4].
Women using oral contraceptives or hormone replace-
ment therapy tend to have higher levels than other
women [5]. The possibility exists that endogenous estro-
gen is also associated with CRP [10], hence menopausal
status may contribute to differences in CRP between the
older AusDiab and younger DRUID women, but we do
not have data to examine this. However, the data pre-
sented by Wang and Hoy [24] on CRP levels with age
do not indicate any change in the association at an age
where most women would reach menopause.
The significance of higher CRP in women than men
across two very different populations is not clear. CRP
is known to be associated with CHD, and typically men
are considered to be at higher risk than women [27]. A
recent review suggested that global inflammation, as
indicated by elevated CRP, may predict cardiovascular
outcomes in women better than the traditional risk fac-
tors identified in men [27]. Onat et al on the other hand
found that CRP predicted CHD similarly in Turkish
men and women, but diabetes in women only [3]. In
either case, the extremely high CRP concentrations seen
in the DRUID women could presage extremely high
rates of diabetes and CHD, although no prospective
data is available to confirm this.
It is of interest that in our multivariate models current
smoking was associated with elevated CRP in men only.
In a Turkish population-based study, smoking in
women was actually associated with a lower CRP con-
centration than in non-smokers, while in men smokers
had higher CRP than non-smokers [3].
In a recent study of Native Alaskans, CRP was found
to be associated with pathogen burden, measured as
IgG, IgA and IgM antibodies to C. pneumoniae and IgG
antibodies to other pathogens [28]. High CRP levels
seen in Indigenous Australians, particularly those above
10 mg/L, may be in part attributable to pathogen bur-
den. For example, the prevalence of H. pylori in two
Indigenous populations in Western Australia was extre-
mely high, 91% in a remote community and 60% in an
urban community, which is still twice what would be
expected in the non-Indigenous Perth population [29].
High rates of acute otitis media related to infections
with H. influenzae and S. pneumoniae are common in
Indigenous children [30]. McDonald et al [31] found
that higher CRP concentrations in a group of remote
Australian Aborigines were associated with IgG seropo-
sitivity to H. pylori and C. pneumoniae and higher IgG
titre for cytomegalovirus.
Our study has several limitations. The data are cross-
sectional, and we are unable to comment on the repre-
sentativeness of volunteer cohorts with low to moderate
response rates. There is evidence that people who
attended the AusDiab follow-up were healthier than
those who did not attend [18], which would suggest
they may have lower CRP concentrations than the more
representative original sample. This may explain to
some extent their lower unadjusted CRP levels relative
to DRUID participants. However, the multivariate analy-
sis accounted for many health related variables, both
risk markers (lipids, glucose tolerance, blood pressure,
obesity) and behavioural factors (smoking), which
appeared to largely explain the differences between
DRUID and AusDiab.
We are unable to account for the use of statins, which
can reduce CRP levels [32], in DRUID. However, we do
have data for all but 23 men and 18 women on lipid
lowering medication, which includes statins. Adding an
indicator variable for lipid-lowering medication did not
markedly change the ORs for DRUID relative to Aus-
Diab from those presented in Table 2; although in
women, such drug use was associated with a reduced
risk of high CRP.
The assay methods used for hs-CRP in both studies
were different and we do not have data to directly evalu-
ate their comparability. Roberts et al [33] compared 9
hs-CRP methods, including the DPC and Roche meth-
ods, with the DadeBehring BN II assay. Although both
showed good concordance with the reference method,
the Roche assay tended to give slightly higher results
and correctly classified around 75% of 388 blood donors
into quartiles based on the Dade method, while the
DPC assay correctly classified around 95% [33]. None-
theless, criteria proposed to identify high risk CRP con-
centrations do not specify the method, and are widely
applied. The difference between assays could potentially
contribute to higher hs-CRP values in DRUID using the
Roche assay, but is unlikely to explain the large differ-
ences in crude CRP concentrations observed.
The main strength of our study is that we were able to
combine data, collected using similar methods, from
population based studies of the general population and
an Indigenous Australian population.
Conclusion
We have reported high levels of CRP in Indigenous
Australians in the DRUID study, associated with adverse
risk factor profiles. After adjusting for risk factors, in
particular abdominal obesity, glucose tolerance, HDL
cholesterol, diastolic blood pressure and smoking status,
CRP levels in DRUID were no longer significantly differ-
ent to AusDiab, but women in both groups had higher
CRP values than men. Whether CRP is an independent
risk factor for coronary heart disease is debatable
[32,34]. Irrespective of its independence as a risk factor,
or its aetiological association with CHD, the particularly
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high circulating CRP levels seen in the urban Indigenous
women in association with increased abdominal fat are
likely to reflect increased vascular disease and metabolic
risk, and point to the need for interventions to address
this. The significance of elevated CRP in Indigenous
Australians should be investigated in future longitudinal
studies to determine its significance as a predictor of
future diabetes and CHD, and if relevant, reducing CRP
may be an important target of interventions to improve
the health of Indigenous Australians.
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